Search Results
Your search for AT matches 29019 pages
Showing 10501 - 10550Expert Point of View: David Wise, MD and Celestia S. “Tia” Higano, MD, FACP
“GnRH antagonists have several advantages over GnRH agonists,” explained David Wise, MD, of Perlmutter Cancer Center at NYU Langone Health in New York. “There is no testosterone flare on initiation [as there is with leuprolide], no increase in cardiac toxicity, and faster onset of action. Currently ...
Novel Androgen-Deprivation Therapy With Relugolix Causes Fewer Cardiac Events Than Leuprolide in Advanced Prostate Cancer
Men with prostate cancer on androgen-deprivation therapy are usually treated with leuprolide, a long-acting injectable luteinizing hormone-releasing hormone (LHRH) agonist requiring an every-3-month injection, but it may be possible for ADT to be delivered by a daily oral treatment, pending...
Biomarker Combination May Help Predict Response to Immunotherapy in Patients With Metastatic Urothelial Carcinoma
In patients with metastatic urothelial carcinoma, a novel combination of biomarkers from baseline tumor tissues was predictive of improved clinical responses and prolonged survival following treatment with immune checkpoint inhibitors, according to findings published by Goswami et al in Science...
Mortality Risk in Patients With COVID-19 and Thoracic Malignancies: Initial Report From the TERAVOLT Registry Study
As reported in The Lancet Oncology by Marina C. Garassino, MD, and colleagues, initial findings from the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry study have identified potential factors associated with increased risk of mortality in patients infected with COVID-19...
Novel Risk Calculator for Sentinel Node Positivity in Patients With Melanoma
As reported in the Journal of Clinical Oncology, Lo et al developed a novel risk calculator for sentinel node metastasis—the Melanoma Institute Australia Nomogram—that appears to more accurately predict risk of metastasis in patients with primary cutaneous melanoma than other commonly used risk...
Long-Term Outcomes With Pembrolizumab for Cisplatin-Ineligible Advanced Urothelial Cancer
As reported in the Journal of Clinical Oncology by Vuky et al, long-term follow-up in the phase II KEYNOTE-052 study has shown durable responses with first-line pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer, with higher response rates and longer survival in...
Addition of Rituximab to Standard Chemotherapy in Pediatric Patients With High-Risk, Mature B-Cell Non-Hodgkin Lymphoma
In a European Intergroup for Childhood Non-Hodgkin Lymphoma/Children’s Oncology Group phase III trial reported in The New England Journal of Medicine, Minard‑Colin et al found that the addition of rituximab to standard Lymphomes Malin B (also known as Lymphome Malin de Burkitt, or LMB) chemotherapy ...
Variant in Gene May Increase Cancer Risk in Those With Common TP53 R337H Mutations
Scientists studying a common TP53 R337H variant found among people of Brazilian descent discovered that a variant in the tumor-suppressor gene XAF1 increases cancer risk when combined with the inherited TP53 R337H mutation. These findings were published by Pinto et al in Science Advances. “We...
Sedentary Behavior and Risk of Cancer Mortality
In a study that investigated objective measures of sedentary behavior and cancer mortality, researchers found that greater inactivity was independently associated with a higher risk of dying from cancer. An accelerometer was used to measure physical activity, rather than relying on participants to...
Long-Term Survival Outcomes With Different Durations of Adjuvant Imatinib for Gastrointestinal Stromal Tumors
In a 10-year follow-up of the phase III SSGXVIII/AIO trial reported in JAMA Oncology, Heikki Joensuu, MD, and colleagues found that 3 years vs 1 year of adjuvant treatment with imatinib was associated with superior overall survival among patients with high-risk gastrointestinal stromal tumors. The ...
Effect of Radiation Boost to Residual Disease in High-Risk Neuroblastoma
In an analysis from the Children’s Oncology Group (COG) ANBL0532 study reported in the Journal of Clinical Oncology, Liu et al found that a radiotherapy boost to the gross residual tumor in patients with high-risk neuroblastoma did not appear to improve outcomes compared with patients in another...
Leaders of the PROMISE Study Address Racial Inequities in the United States
In 2018, researchers from Dana-Farber Cancer Institute launched a large, ambitious screening study called PROMISE (ClinicalTrials.gov identifier NCT03689595). The objectives of the study were to identify people with premalignant precursor conditions of multiple myeloma, understand the molecular...
Conquer Cancer Honors Early-Career Medical Professionals From Around the World
Conquer Cancer®, the ASCO Foundation honored recipients of the 2020 Medical Student Rotation for Underrepresented Populations (MSR), Resident Travel Awards for Underrepresented Populations (RTA), Long-Term International Fellowship (LIFe), and International Development and Education Awards (IDEA)...
Association of American Cancer Institutes Issues Statement About Racial Discrimination
In further statements from professional oncology organizations about inequities and disparities among racial and ethnic minorities and underserved populations, as well as racism and discrimination, the Association of American Cancer Institutes (AACI) issued the following statement: The AACI...
I’m Not Too Young for Colorectal Cancer
The first symptoms I had of colorectal cancer—blood in my stool and abdominal pain—coincided with surgery I had to remove my appendix in the spring of 2017. My surgeon attributed the symptoms to the appendectomy and to the medications I received both before and after the surgery. In addition to...
AMA Announces New President and President-Elect
Susan R. Bailey, MD, an allergist from Fort Worth, recently took office as the 175th President of the American Medical Association (AMA), the nation’s premier physician organization. Dr. Bailey is the third consecutive woman to hold the office, a record for the AMA. In addition, the organization...
AMA Board of Trustees Pledges Action Against Racism and Police Brutality
At a virtual Special Meeting of the American Medical Association (AMA) House of Delegates, the AMA Board of Trustees pledged action to confront systemic racism and police brutality. The AMA released the following statement that was approved at its meeting on June 5, 2020: The AMA recognizes that...
New Information From NCCN on Overcoming Challenges for People With Head and Neck Cancer
The National Comprehensive Cancer Network® (NCCN®) has now published a third book to complete the NCCN Guidelines for Patients®: Head and Neck Cancers series. Each book contains detailed, expert guidance on what to expect and management options for various cancers that impact the mouth and throat....
Melanoma Awareness: Outlook From a Young Adult
When I was 18, I was diagnosed with stage II melanoma. I had a strange spot on my back that I mentioned to my dermatologist, almost as an afterthought. It never occurred to me it could be skin cancer, let alone the most dangerous kind. I have fair skin but was by no means a sun worshipper. My...
Initiate Conversations About Radiation Therapy for Bone Metastases
Although the American Society for Radiation Oncology (ASTRO) has recommended extended-fraction radiation therapy (more than 10 fractions) not be routinely used for palliation of bone metastases,1 a recently published retrospective cohort study using Medicare data for more than 12,000 patients found ...
Extended-Fraction Radiation Therapy for Bone Metastases Represents Low-Value Care but Continues to Be Widely Practiced
An analysis of radiation therapy patterns among more than 12,000 Medicare patients treated for bone metastases found that 23.4% received extended-fraction radiation therapy, “wasting both health-care dollars and precious patient time,” according to the investigators.1 One-third of the treating...
An Honored Poet Explores a Lust for Life on the Boundaries of Near Death
"When the technician leaves the room, I turn my head toward the screen to interpret neoplasms, the webs of nerves, the small lit fonts in which my pathology and/or future or future end might be written. The first tumor I ever saw was a darkness on that screen, round with a long craggy finger...
Integrating Physical Activity Into Cancer Care
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Accumulating evidence suggests the benefits of physical activity through the cancer continuum....
Capmatinib for Metastatic NSCLC With MET Exon 14 Skipping Mutation
On May 6, 2020, the oral mesenchymal-epithelial transition (MET) kinase inhibitor capmatinib was granted accelerated approval for the treatment of adult patients who have metastatic non–small cell lung cancer (NSCLC) with tumors that have a mutation that leads to MET exon 14 skipping, as detected...
AIDS Research Led to Appreciation of the Power of Plants and Integrative Medicine in Cancer Care for Donald I. Abrams, MD
The path that led Donald I. Abrams, MD, to a career in oncology was a circuitous one. Although his love of science began when he was a student at Cleveland Heights High School in Ohio, and continued during college at Brown University, where he received an AB in molecular biology in 1972, he was...
NCI Renews Comprehensive Cancer Center Designation for Norris Cotton Cancer Center
The National Cancer Institute (NCI) has renewed its Cancer Center Support Grant to Dartmouth and Dartmouth-Hitchcock Norris Cotton Cancer Center (NCCC). The 5-year, $15.5 million grant will provide continued support for NCCC’s clinical care and research missions. NCI recognized the cancer center...
COVID-19 and Patients With Cancer: A Call to Action for Trainees
As oncology trainees, we develop skills to synthesize complex data and communicate this information with empathy as we accompany our patients through the trenches of a cancer diagnosis. With the current COVID-19 pandemic, an unprecedented layer of challenges has surfaced, as our patients who are...
Do You Know About ASCO’s Patient Education Materials?
ASCO Answers is a collection of oncologist-approved patient education materials developed by ASCO for people with cancer and their caregivers. ASCO Answers materials have everything your patients need to understand and manage their disease. From comprehensive guides to topic-specific booklets and...
Pigeon English
The ASCO Post is pleased to reproduce installments of Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of tolerating cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays, historical...
ASCO Welcomes 2020–2021 Board of Directors
ASCO is pleased to welcome the 2020–2021 Board of Directors and introduce the newly installed leaders who began their terms at the conclusion of the Annual Business Meeting on June 1, 2020. ASCO and the Board of Directors extend their sincere gratitude to the outgoing Board members whose terms...
Small Study Finds Olanzapine Reduces Nausea and Vomiting Caused by Advanced Cancer
The antipsychotic agent olanzapine may be helpful in reducing nausea and vomiting caused by advanced cancer, according to results of a study by Loprinzi et al published recently in JAMA Oncology. “There was a dramatic reduction [in nausea and vomiting] within 24 hours in the people who received...
Penn Medicine Announces Appointment of Daniel Yoshor, MD, as Chair, Department of Neurosurgery
Neurosurgeon and neuroscientist Daniel Yoshor, MD, has been named Chair of the Department of Neurosurgery in the Perelman School of Medicine at the University of Pennsylvania and Vice President of Clinical Integration and Innovation for the University of Pennsylvania Health System in Philadelphia. ...
American Urological Association Recognizes Roswell Park Surgeon Eric Kauffman, MD
Eric Kauffman, MD, was recently recognized by the American Urological Association for his novel approach to prostate cancer surgery, receiving a Best Video award for 2020. Dr. -Kauffman is a surgeon in the Department of Urology at Roswell Park Comprehensive Cancer Center, Buffalo. His video...
Polio and Cancer Survivor Mickie McGraw Channels the Power of Creative Arts to Heal Broken Bodies and Minds
GUEST EDITOR Dr. Abraham is Professor of Medicine, Lerner College of Medicine, and Chair of the Hematology and Medical Oncology Department at Taussig Cancer Institute, Cleveland Clinic. In this edition of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with pioneering art ...
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
Question 1 Which of the following statements about mixed-cellularity classic Hodgkin lymphoma is correct? A. It has a female predominance. B. This type of classic Hodgkin lymphoma is relatively more common in developing nations and is frequently associated with Epstein-Barr virus (EBV) positivity....
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this first-part of a two-part installment, Drs. Abutalib and Medeiros highlight the histologically rare lymphocyte-rich type of classic Hodgkin lymphoma,...
Pomalidomide for Treatment of Kaposi Sarcoma
On May 14, 2020, pomalidomide was granted accelerated approval to treat adult patients with AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy and for Kaposi sarcoma in adult patients who are HIV-negative.1,2 Pomalidomide is available only through the restricted...
Seattle Cancer Care Alliance Opens New Clinic Dedicated to Gastrointestinal Cancer Care
Seattle Cancer Care Alliance (SCCA) announced the opening of a Gastrointestinal (GI) Care Neighborhood, a new cancer clinic aimed at improving the experience for patients with GI cancers, which features dedicated GI-related cancer care services on one floor of SCCA’s South Lake Union campus. “We...
Study Confirms Effective, Less-Toxic Alternative to Standard Treatment of Adults With Burkitt Lymphoma
In a recent study reported in the Journal of Clinical Oncology,1 an alternative treatment regimen that is less toxic than standard dose-intensive chemotherapy was found to be highly effective for adults with Burkitt lymphoma across all age groups and independent of HIV status. In addition to being...
You-Can-Do-Anything Philosophy Early in Life Inspired Breast Surgeon Laura S. Dominici, MD
Breast surgical oncologist Laura S. Dominici, MD, was born and reared in Litchfield, a small town in the southern portion of New Hampshire. “Our house was on a long dirt road, in a very rural area,” she shared. “There were only about 5,000 residents in the town. My mother was a teacher, and my dad...
Expert Point of View: Komal Jhaveri, MD, FACP
Komal Jhaveri, MD, FACP, Attending Physician at Memorial Sloan Kettering Cancer Center, Clinical Director of the Early Drug Development Service, and Assistant Professor of Medicine at Weill Cornell Medical College, served as the study’s invited discussant. Dr. Jhaveri noted that, in SOLAR-1, the...
Woman With an Ovarian Tumor
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Anesthesia Era: 1845–1875 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
Study Identifies Potential Approach to Treat Severe Respiratory Distress in Patients With COVID-19
Early data from a clinical study published in Science Immunology1 suggest that blocking the Bruton’s tyrosine kinase (BTK) protein provided clinical benefit to a small group of patients with severe COVID-19 infection.1 Roschewski et al observed that the off-label use of the BTK inhibitor...
Study Finds Alpelisib Effective After CDK4/6 Inhibition in Advanced Breast Cancer
The PIK3CA inhibitor alpelisib appears to be effective in patients with PIK3CA-positive, hormone receptor–positive/HER2-negative advanced breast cancer previously treated with a cyclin-dependent kinase (CDK) 4/6 inhibitor plus an aromatase inhibitor, according to the phase II BYLieve trial.1 More...
Survey Shows Young-Onset Colorectal Cancer May Be Overlooked in Exam Rooms
The Colorectal Cancer Alliance recently released findings from its latest survey of patients with young-onset colorectal cancer and survivors. The Never Too Young Survey shares the self-reported medical, psychosocial, and quality-of-life experiences of this often-overlooked population to better...
ASCO20 Virtual Scientific Program: Next-Generation Oncology Highlights
The ASCO20 Virtual Scientific Program was different in many ways, not only because of the virtual modality forced by the COVID-19 pandemic, but also because of the resilience of the scientific society and my colleagues around the world. I’m in the plenary session of the ASCO 2025 Annual Meeting....
American Association for Cancer Research Announces Distinguished Public Service Award Recipients
The American Association for Cancer Research (AACR) recently announced the presentation of Distinguished Public Service Awards to four individuals whose work has exemplified the AACR’s mission to prevent and cure all cancers through research, education, communication, collaboration, science policy, ...
MSK–Hackensack Meridian Health Partnership Collaborate on Immunology Research Projects
Memorial Sloan Kettering Cancer Center (MSK) and Hackensack Meridian Health recently announced they have formed an Immunology Research Collaboration. Through this joint initiative, researchers can apply for funding to support innovative investigations exploring the power of the immune system and...
Fox Chase–Temple University Hospital Announces Bone Marrow Transplant Program
The Fox Chase–Temple University Hospital Bone Marrow Transplant (BMT) Program recently announced it will introduce a Department of Bone Marrow Transplant and Cellular Therapies on July 1, 2020. Henry Chi Hang Fung, MD, FACP, FRCPE, Current Director of the Bone Marrow Transplant Program and Vice...
Brigatinib for ALK-Positive Metastatic Non–Small Cell Lung Cancer
On May 22, 2020, brigatinib was approved for the treatment of adult patients with ALK-positive, metastatic non–small cell lung cancer (NSCLC), as detected by a U.S. Food and Drug Administration (FDA)-approved test.1,2 The FDA also approved the Vysis ALK Break Apart FISH Probe Kit as a companion...
